Molecular mechanisms of drugs recommended in COVID-19 treatment
DOI:
https://doi.org/10.2478/pjph-2020-0014Keywords:
COVID-19, SARS-CoV-2 virus, remdesivir, tocilizumab, convalescent plasma, corticosteroids, anticoagulantsAbstract
The development of an effective treatment for COVID-19 is now one of the main tasks of scientists and doctors from all over the world. The rapidly spreading SARS-CoV2 virus infection is a serious health problem among the public. Similarity of SARSCoV2 to MERS-CoV and SARS-CoV may suggest the effectiveness of COVID-19 treatment with drugs used to fight infections of previously identified Coronaviridae viruses. On the basis of gained experience and new clinical trials, the Polish Society of Epidemiologists and Infectious Diseases Physicians has created guidelines for the treatment of COVID-19.The recommendations concern primary and supportive treatment at different stages of the disease. This article provides a brief review of the molecular mechanisms of drugs currently used in Poland for the treatment of COVID-19.
References
1. Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536-44.
2. Shereen A, Khan S, Kazmi A, et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Advanc Res. 2020;24:91-8.
3. Ashour H, Elkhatib W, Rahman M, et al. Insights into the recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020;9(3):186.
4. Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11.
5. World Health Organization (WHO). Coronavirus. Geneva: WHO; 2020. [https://www.who.int/health-topics/coronavirus]
6. WHO Director-General’s opening remarks at the media briefing on COVID-19. [https://www.who.int ]
7. Chan JFW, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Emerg Microbes Infect. 2020;9:221-36.
8. Satarker S, Nampoothiri M. Structural proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Arch Med Res. 2020;51(6):482-91.
9. Chan JFW, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coro - navirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221-36.
10. Deng SQ, Peng HJ. Characteristics of a public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9(2):575.
11. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(8).
12. Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Coronaviruses. 2015;1282:1-23.
13. Jaimes JA, André NM, Chappie JS, et al. Phylogenetic analysis and structural modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically-Sensitive Activation Loop. J Mol Biol. 2020;1-17.
14. Duart G, García-Murria MJ, Grau B, et al. SARS-CoV-2 envelope protein topology in eukaryotic membranes. Open Biol. 2020;10(9):200-9.
15. Fang X, Gao J, Zheng H. The Membrane Protein of SARS-CoV Suppresses NF-kB Activation. J Med Virol. 2007;79:1431–1439.
16. Alsaadi EAJ, Jones IM, Membrane binding proteins of coronaviruses. Future Virol. 2019;14:275-86.
17. Tsoi H, Li L, Chen ZS, et al. The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1PKB/Akt signalling. Biochem J. 2014;464:439-47.
18. Velavan TP, Meyer C. The Covid-19 epidemic. Tropical Med Int Health. 2020;25(3):278-80.
20. Warren T, Jordan R, Lo M, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381-5.
21. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773-9.
22. Sun D. Remdesivir for treatment of COVID-19: Combination of pulmonary and IV administration may offer aditional benefit [published correction appears in AAPS J. 2020;22(5):102]. AAPS J. 2020;22(4):77.
23. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020;30:269-71.
24. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117:6771-6.
25. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Commun. 2020;11:222.
26. Sun M, Xu Y, He H, et al. A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis. 2020;98:334-46.
27. Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
28. Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507-13.
29. Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
30. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970-5.
31. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537
32. Pathak EB. Convalescent plasma is ineffective for covid-19. BMJ. 2020;371:m4072.
33. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7.
34. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-6.
35. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;324(8):782-93.
36. Shi C, Tingting W, Li JP et al. Comprehensive landscape of heparin therapy for COVID-19. Carbohydr Poly. 2020;117232.
37. Davies R., Choy E., Clinical experience of IL-6 blockade in rheumatic diseases–Implications on IL-6 biology and disease pathogenesis. Semin Immunol. 2014;26:97-104.
38. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1):11-20.
39. Scott LJ. Tocilizumab: A review in rheumatoid arthritis. (Published correction appears in Drugs). Drugs. 2017;77(17):1865-79.
40. Dhillon S. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. Bio Drugs. 2014;28(1):75-106.
41. Ramamoorthy S, Cidlowski JA. Corticosteroids-mechanisms of action in health and disease. Rheum Dis Clin N Am. 2016;42(1):15-31.
42. Ahmed MH, Hassan A. Dexamethasone for the treatment of coronavirus disease (COVID-19): A Review. SN Compr Clin Med. 2020;1-10.
43. Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician. 1998;58(2):443-50.
44. Chikanza IC. Mechanisms of corticosteroid resistance in rheumatoid arthritis: a putative role for the corticosteroid receptor beta isoform. Ann N Y Acad Sci. 2002;966:39-48.
45. Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signaling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol. 2000;130:289-98.
46. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864-8.
47. Mitre-Aguilar IB, Cabrera-Quintero AJ, Zentella-Dehesa A. Genomic and non-genomic effects of glucocorticoids: implications for breast cancer. Int J Clin Exp Pathol. 2015;8(1):1-10.
48. Grzanka A, Misiołek M, Golusiński W, Jarząb J. Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis. Eur Arch Otorhinolaryngol. 2011;268:247-53.
49. Ortolani C, Pastorello EA. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost? Clin Mol Allergy. 2020;18:17.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Polish Journal of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
